1. Home
  2. MEGL vs INDP Comparison

MEGL vs INDP Comparison

Compare MEGL & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Magic Empire Global Limited

MEGL

Magic Empire Global Limited

N/A

Current Price

$1.12

Market Cap

5.1M

Sector

Finance

ML Signal

N/A

Logo Indaptus Therapeutics Inc.

INDP

Indaptus Therapeutics Inc.

HOLD

Current Price

$2.15

Market Cap

4.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MEGL
INDP
Founded
2016
2000
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.1M
4.7M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
MEGL
INDP
Price
$1.12
$2.15
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
12.5K
36.4K
Earning Date
04-17-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.87
$0.27
52 Week High
$2.62
$13.24

Technical Indicators

Market Signals
Indicator
MEGL
INDP
Relative Strength Index (RSI) 61.25 59.55
Support Level $1.01 $1.64
Resistance Level $1.13 $2.08
Average True Range (ATR) 0.03 0.19
MACD 0.00 0.05
Stochastic Oscillator 100.00 89.06

Price Performance

Historical Comparison
MEGL
INDP

About MEGL Magic Empire Global Limited

Magic Empire Global Ltd is a financial services provider in Hong Kong which principally engage in the provision of corporate finance advisory services and underwriting services. The companys offerings mainly comprise of IPO sponsorship services, Financial advisory and independent financial advisory services, Compliance advisory services, Underwriting services, Corporate service.

About INDP Indaptus Therapeutics Inc.

Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.

Share on Social Networks: